ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
Pink SheetUS Centers for Medicare and Medicaid Services Administrator nominee Mehmet Oz is committed to defending the Medicare price negotiation program, but will pursue other ways to lower drug costs if confir
ScripBristol Myers Squibb is moving to take over its longtime cell therapy partner 2seventy bio and the CAR-T cell therapy they developed and commercialized together, Abecma (idecabtagene vicleucel). The b
Pink SheetAdvanced therapy medicinal products (ATMPs) typically come with high price tags compared to more traditional medicinal treatments. While health technology assessment (HTA) agencies are willing to exer